Date:
Tue, 20 Oct 2026 09:04:40 EDT
Content:
The U.S. Food and Drug Administration (FDA) has published a new entry regarding Linde Inc., specifically focusing on its operations located in Stockertown, Pennsylvania. This update serves as part of the agency’s ongoing regulatory oversight of facilities involved in the production of medical-grade gases and related products.
The documentation references a specific report or inspection status dated March 26, 2023, under the identification number 2523830. These records typically outline facility compliance, manufacturing standards, and adherence to federal safety protocols. The Stockertown site is a key component of Linde’s regional manufacturing and distribution network.
Industry stakeholders and healthcare providers can access the full details of this update through the FDA’s official transparency portal. Regular monitoring of these reports ensures that manufacturing entities maintain the high standards required for products entering the healthcare supply chain.
Source: FDA.gov
Link:
http://www.fda.gov/about-fda/linde-inc
Keywords:
FDA, Linde Inc, Stockertown PA, medical gas, facility inspection, regulatory compliance